ERBB2 and breast carcinoma: T-DM1 prolonged PFS and OS in patients with HER2-positive breast cancer in the metastatic setting (Verma et al., 2012) and in the adjuvant setting in patients with residual disease after neoadjuvant treatment (von Minckwitz et al., 2019).